Literature DB >> 2161581

Recombinant bovine interferon-gamma, but not interferon-alpha, potentiates bovine neutrophil oxidative responses in vitro.

A K Sample1, C J Czuprynski.   

Abstract

In this study we have addressed the in vitro effects of recombinant bovine interferon-gamma (rBoIFN-gamma) and interferon-alpha (rBoIFN-alpha 1) on oxidative functions of bovine neutrophils. Treatment with rBoIFN-gamma, but not rBoIFN-alpha 1, enhanced the luminol-dependent chemiluminescence (LDCL) response of bovine neutrophils to both opsonized zymosan particles and phorbol myristate acetate. Pre-incubation of neutrophils for 2 h at 39 degrees C with rBoIFN-gamma resulted in a 40% increase in both LDCL and release of hydrogen peroxide by neutrophils stimulated with opsonized zymosan. This enhancement was observed at doses ranging from 0.2 to 2000 units of rBoIFN-gamma per ml. In contrast to the results observed in the LDCL and hydrogen peroxide assays, preincubation of neutrophils with rBoIFN-gamma had no effect on the levels of superoxide anion released in response to opsonized zymosan. Pre-incubation with rBoIFN-gamma increased phorbol myristate acetate (PMA)-stimulated LDCL by 30%, although it had no effect on either superoxide anion or hydrogen peroxide release in response to PMA stimulation. Neither recombinant interferon directly elicited an oxidative burst from neutrophils in the absence of zymosan or PMA stimulation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161581     DOI: 10.1016/0165-2427(90)90107-4

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  2 in total

1.  Elimination of hydrogen peroxide by Haemophilus somnus, a catalase-negative pathogen of cattle.

Authors:  A K Sample; C J Czuprynski
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

Review 2.  Interferon-gamma activation of polymorphonuclear neutrophil function.

Authors:  Terri N Ellis; Blaine L Beaman
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.